- Home
- IPHA vs FENC Comparison
IPHA vs FENC Comparison
Compare IPHA & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPHA | FENC |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.2M | 258.5M |
| IPO Year | 2019 | 2001 |
Fundamental Metrics
Financial Performance| Metric | IPHA | FENC |
|---|---|---|
| Price | $1.89 | $7.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $5.00 | ★ $13.50 |
| AVG Volume (30 Days) | 22.5K | ★ 200.2K |
| Earning Date | 09-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $14,839,695.00 | ★ $38,790,000.00 |
| Revenue This Year | $22.29 | N/A |
| Revenue Next Year | $43.90 | $75.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.47 | $4.68 |
| 52 Week High | $3.51 | $9.92 |
Technical Indicators
Market Signals| Indicator | IPHA | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 41.95 |
| Support Level | $1.85 | $7.35 |
| Resistance Level | $1.91 | $7.74 |
| Average True Range (ATR) | 0.06 | 0.36 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 30.23 | 18.89 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.